H. Lundbeck A/S has reported robust financial results for the first half of 2025, with total revenue increasing by +14% CER (+14% DKK) to DKK 12,258 million. The growth was primarily driven by strong performance in the U.S. and European markets. Lundbeck’s strategic brands saw a significant revenue boost of +21% CER (+21% DKK), totaling DKK 9,436 million, which accounted for 77% of the total revenue.
The company’s adjusted EBITDA surged to DKK 4,221 million, marking a growth of +24% CER (+25% DKK). This increase was attributed to the continuous strong momentum across strategic brands, notably Vyepti® and Rexulti®, and the effective execution of the Focused Innovator Strategy. The adjusted EBITDA margin also saw a notable improvement, reaching 34.4% (DKK), reflecting a 3.1 percentage point increase. This was supported by disciplined resource allocation and capital reallocation aligned with the company’s strategic direction.
Following the impressive performance in H1 2025, Lundbeck raised its full-year revenue and adjusted EBITDA guidance at CER. The company now anticipates revenue growth of 11% to 13% at CER and adjusted EBITDA growth of 16% to 21% at CER. Lundbeck’s President and CEO, Charl van Zyl, expressed satisfaction with the first-half results and highlighted the company’s strong outlook for the remainder of the year. He emphasized the pivotal role of the Focused Innovator strategy and successful capital reallocation initiatives in driving sustained growth, particularly through strategic brands like Vyepti® and Rexulti®.
In other recent developments, the U.S. Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee cast a negative vote on the efficacy of brexpiprazole with sertraline for PTSD. This decision, based on the available evidence, will be factored into the ongoing FDA review process. Furthermore, Lundbeck obtained orphan drug designation from both the FDA and the EMA for Lu AG13909, a novel monoclonal antibody under investigation for treating Congenital Adrenal Hyperplasia (CAH), a rare genetic disorder.
Lundbeck also shared positive outcomes from recent trials, including the phase IV RESOLUTION trial and the SUNRISE trial, both evaluating eptinezumab for chronic migraine. These studies demonstrated promising results in reducing migraine days, severe pain episodes, and overall disease burden compared to placebo. Additionally, Lundbeck successfully secured EUR 500 million in senior unsecured notes, further strengthening its financial position.
Looking ahead, Lundbeck will host a conference call for the financial community to discuss these developments and the company’s future prospects. The continual focus on innovation and strategic growth initiatives positions Lundbeck favorably for the remainder of 2025 and beyond.
Key Takeaways:
– Lundbeck’s strong H1 2025 performance led to an upward revision of its full-year revenue and adjusted EBITDA guidance at CER.
– The company’s strategic brands, Vyepti® and Rexulti®, played a significant role in driving revenue growth and market share expansion.
– Recent trial results have shown the potential of Lundbeck’s products in addressing unmet medical needs, particularly in migraine treatment.
– Lundbeck’s successful financial initiatives, such as securing senior unsecured notes, reflect a commitment to maintaining a robust financial position amidst growth opportunities.
Read more on finanznachrichten.de